A Phase 2 interventional study of HS-20137 in Moderate-to-severe Plaque Psoriasis, sponsored by Hansoh BioMedical R&D Company. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited — 7 open to participants now, 7 under way, 2 of them phase 3. Psoriasis · Hansoh Pharmaceutical Group Company Limited.
Among the 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited, this one is the 2nd largest by planned enrollment, is one of 6 that started in 2025, is one of 4 in phase 2, and was the 10th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →7 of the 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited are open now, in 1 country. Recruiting first, the newest first:
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Hansoh BioMedical R&D Company · Sites in China
Ages 18–70
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Ages 18+
Hansoh BioMedical R&D Company
Ages 18+
Hansoh BioMedical R&D Company · Sites in China
Ages 18–70
By country, each count listing its studies:
Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 6 started in 2025.
This study's planned enrollment of 390 is above the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 131 across the 10 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Hansoh BioMedical R&D Company, one of the names counted as Hansoh Pharmaceutical Group Company Limited. Under that name alone:
Hansoh BioMedical R&D Company is the lead sponsor of 48 studies on the registry; 43 are open to participants now.
3 of the studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06844799Phase 3Hansoh BioMedical R&D CompanyA Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis | 2027-03-31 |
| NCT07765628Jiangsu Hansoh Pharmaceutical Co., Ltd.A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis | 2027-02-28 |
| NCT07879885Hansoh BioMedical R&D CompanyAn Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis | 2027-03-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of HS-20137 in the treatment of participants with moderate-to-severe plaque psoriasis
HS-20137 is an antibody targeting interleukin-23 (IL-23), a key cytokine involved in the pathogenesis of psoriasis. IL-23-targeting biologic agents are recommended for the treatment of patients with moderate-to-severe psoriasis. This is an open-label, Phase 2, single-arm interventional study, including a 4-week screening period, a 16-week treatment period and a 4-week follow-up period (total 24 weeks). Participants with moderate-to-severe plaque psoriasis will be enrolled in this study and will receive HS-20137 200 mg at weeks 0, 4 and 8. The primary objective is to evaluate the safety and tolerability of HS-20137. Secondary objectives are to evaluate the efficacy and immunogenicity of HS-20137
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of the following drugs before the first dose:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive HS-20137 by subcutaneous injection at weeks 0, 4 and 8
Biological: HS-20137
HS-20137 200 mg injection at weeks 0, 4 and 8
Also known as: QX004N
Number of Participants with Adverse Events
Adverse events will be assessed for incidence, severity, relationship to study intervention, duration, and outcome.
Time frame: up to 20 weeks
Changes From Baseline in Clinical Laboratory Test Results
Changes from baseline in protocol-specified clinical laboratory test results following administration of HS-20137 will be assessed.
Time frame: Frame: up to 20 weeks
Changes From Baseline in Physical Examination Findings
Changes from baseline in physical examination findings following administration of HS-20137 will be assessed.
Time frame: up to 20 weeks
Changes From Baseline in Vital Signs
Changes from baseline in protocol-specified vital signs following administration of HS-20137 will be assessed.
Time frame: up to 20 weeks
Incidence of Clinically Significant Electrocardiogram (ECG) Abnormalities
The incidence of clinically significant electrocardiogram (ECG) abnormalities following administration of HS-20137 will be assessed.
Time frame: up to 20 weeks
PASI 50, PASI 75, PASI 90, and PASI 100 Response Rates at Each Visit Time Point
The Psoriasis Area and Severity Index (PASI) is a scoring system used to assess the severity of psoriasis based on lesion severity and area of involvement. PASI 50, PASI 75, PASI 90, and PASI 100 response rates are defined as the percentages of participants achieving at least 50%, 75%, 90%, and 100% reduction, respectively, in PASI score from baseline. These response rates will be assessed at each visit time point.
Time frame: up to 20 weeks
PASI Scores and Changes From Baseline at Each Visit Time Point
The Psoriasis Area and Severity Index (PASI) score and changes from baseline in PASI score will be assessed at each visit time point.
Time frame: up to 20 weeks
sPGA 0/1 Response Rate at Each Visit Time Point
The static Physician's Global Assessment (sPGA) is a 5-point scale ranging from 0 (clear) to 4 (severe) used to assess the overall severity of psoriasis lesions. The sPGA 0/1 response rate is defined as the percentage of participants achieving an sPGA score of 0 (clear) or 1 (almost clear) at each visit time point.
Time frame: up to 20 weeks
sPGA 0 Response Rate at Each Visit Time Point
The static Physician's Global Assessment (sPGA) is a 5-point scale ranging from 0 (clear) to 4 (severe) used to assess the overall severity of psoriasis lesions. The sPGA 0 response rate is defined as the percentage of participants achieving an sPGA score of 0 (clear) at each visit time point.
Time frame: up to 20 weeks
BSA Scores and Changes From Baseline at Each Visit Time Point
The percentage of body surface area (BSA) affected by psoriasis and changes from baseline in BSA will be assessed at each visit time point.
Time frame: up to 20 weeks
Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 19 months after the start.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's planned 19 months is above that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hansoh BioMedical R&D Company →